Skip to main content
. 2013 Jun 10;13:59. doi: 10.1186/1475-2867-13-59

Table 1.

Association between relaxin-2 mRNA expression and clinicopathologic factors

Clinicopathologic factor Total Serum relaxin-2
 
Relaxin-2 mRNA expression
(mean ± SEM) (ng/mL) P-Value Low(n) High(n) P-Value
Sex
 
 
0.456
 
 
0.568
Female
20
88.24 ± 13.27
 
7
13
 
Male
16
91.58 ± 12.36
 
8
8
 
Age(Years)
 
 
0.087
 
 
0.092
<20
21
95.23 ± 14.16
 
6
15
 
≥20
15
83.62 ± 12.61
 
9
6
 
Tumor location
 
 
0.562
 
 
0.67
Extremity
14
91.54 ± 15.13
 
6
8
 
Axial
22
89.67 ± 14.86
 
9
13
 
Histologic subtypes
 
 
0.893
 
 
0.746
Osteoblastic
12
91.65 ± 13.02
 
5
7
 
Chondroblastic
10
90.54 ± 13.48
 
4
6
 
Fibroblastic
9
89.04 ± 14.23
 
3
6
 
Telangiectactic
5
91.86 ± 13.35
 
3
2
 
Clinical stage
 
 
0.004
 
 
0.018
I + II
20
76. 4 ± 15.27
 
11
9
 
III
16
114.53 ± 17.26
 
4
12
 
Hematogenous metastasis
 
 
0.001
 
 
0.002
No
15
70.53 ± 10.42
 
11
4
 
Yes
21
108.6 ± 14.87
 
4
17
 
Grade
 
 
 
 
 
0.742
High
30
89.12 ± 13.90
0.642
11
19
 
Moderate
3
94.40 ± 12.16
 
2
1
 
Low 3 96.18 ± 12.45   2 1